Cr Pharmaceutical Sustainability Profile
Cr Pharmaceutical, officially known as China Resources Pharmaceutical Group Limited, is a leading player in the pharmaceutical industry, headquartered in Hong Kong. Established in 1992, the company has grown significantly, with a strong presence in major operational regions across China and beyond. Specialising in the research, development, manufacturing, and distribution of a wide range of pharmaceutical products, Cr Pharmaceutical is renowned for its commitment to quality and innovation. Its core offerings include prescription medications, over-the-counter drugs, and healthcare products, all designed to meet the diverse needs of patients and healthcare providers. With a robust market position, Cr Pharmaceutical has achieved notable milestones, including strategic partnerships and expansions that enhance its competitive edge. The company continues to focus on advancing healthcare solutions, solidifying its reputation as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Cr Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cr Pharmaceutical's score of 52 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cr Pharmaceutical's reported carbon emissions
In 2024, Cr Pharmaceutical, headquartered in Hong Kong, reported total carbon emissions of approximately 7,247,000 kg CO2e. This figure includes 937,000 kg CO2e from Scope 1 emissions, 547,436,670 kg CO2e from Scope 2 emissions, and 12,764,000 kg CO2e from Scope 3 emissions. Notably, the Scope 2 emissions are further broken down into 768,000 kg CO2e (location-based) and 2,000 kg CO2e (market-based). The company has set ambitious climate commitments, aiming for a 10% reduction in carbon dioxide emission intensity by the end of the 14th Five-Year Plan period (2025), compared to a baseline of 0.3184 tons/RMB 10,000 in 2020. Additionally, Cr Pharmaceutical targets an 8% decrease in comprehensive energy consumption per RMB 10,000 of added value in Scope 1 emissions over the same timeframe. Looking towards the future, Cr Pharmaceutical has committed to achieving carbon neutrality by 2050 for both Scope 1 and Scope 2 emissions. These targets are part of a broader strategy inherited from its parent company, China Resources Pharmaceutical Group Limited, which influences its sustainability initiatives and performance metrics. Overall, Cr Pharmaceutical's emissions data and climate commitments reflect a proactive approach to reducing its carbon footprint and contributing to global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000 |
| Scope 2 | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 0,000 |
| Scope 3 | - | - | - | - | - | - | - | - | 00,000,000 |
How Carbon Intensive is Cr Pharmaceutical's Industry?
How Carbon Intensive is Cr Pharmaceutical's Location?
Cr Pharmaceutical's Scope 3 Categories Breakdown
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Capital Goods" being the largest emissions source at 16% of Scope 3 emissions.
Top Scope 3 Categories
Cr Pharmaceutical's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cr Pharmaceutical has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
